首页>
美国卫生研究院文献>Journal of Thoracic Disease
>Expert recommendations on the management of childhood bronchial asthma during the novel coronavirus pneumonia epidemic
【2h】
Expert recommendations on the management of childhood bronchial asthma during the novel coronavirus pneumonia epidemic
Novel coronavirus pneumonia (coronavirus disease 2019, COVID-19), first identified in December 2019, is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1). SARS-CoV-2 is sensitive to ultraviolet light and temperature, and can be inactivated by disinfectants, e.g., exposure to 75% ethanol for 30 minutes at 56 °C. SARS-CoV-2 is highly infectious and all populations are equally susceptible, including children (2). As of 12 April 2020, a total of 82,160 cases of COVID-19 had been confirmed in China, and 3341 patients had died (3). Childhood asthma is the most common chronic airway disease in children. During the COVID-19 outbreak, children with asthma may be more susceptible to SARS-CoV-2 infection due to autoimmunity, long-term use of certain drugs and co-existing diseases. Childhood asthma is a chronic respiratory disease that can be exacerbated by environmental pollutants, infectious organisms and psychological factors. Equally, as most children were required to stay at home during the epidemic, exposure to indoor triggers, including dust, anxiety, decreased exercise and reduced visits to the clinic/follow-up, makes the effective management of asthma more difficult. In response to the COVID-19 outbreak, the Paediatric Committee for Allergy, China Association for Promotion of Health Science and Technology convened a panel of experts to put forward suggestions for prevention, environmental intervention, family management, psychological intervention and reasonable exercise for children with asthma, which can be used as a reference for pediatric clinicians and parents.
展开▼
